SynthesisJNCI cancer spectrum2024
Clinical guidelines for the management of mammographic density: a systematic review of breast screening guidelines worldwide.
Synthesis in JNCI cancer spectrum, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Impact of population based breast density notification: multisite parallel arm randomised controlled trial in BreastScreen.BMJ (Clinical research ed.) · 2025Trial
- Radiation dose comparison of photon-counting breast CT and mammography: A phantom study.European journal of radiology open · 2026Article
- WDCN: a comprehensive neural network based approach for estimating breast cancer risk.Briefings in bioinformatics · 2026Article
- Dense Breast Legislation and Supplemental Breast Imaging Among Women Undergoing Mammography.JAMA network open · 2026Article
- Bridging the gap: clinical practice, guidelines, reimbursement and real-world challenges in breast imaging - webinar highlights.Future oncology (London, England) · 2026Article
- Supplemental Breast Ultrasound in Mammography Screening for Women with Critically Dense Breasts.Cancers · 2026Article
- Performance of breast cancer risk prediction algorithms across mammography systems in the UK screening programme.NPJ digital medicine · 2026Article
- Real-world evidence of mammography screening from the Hong Kong Breast Cancer Registry: a cost minimisation analysis of 15 144 patients with breast cancer.BMJ public health · 2026Article
- Assessment of knowledge and awareness regarding breast density among breast cancer screening healthcare professionals.Frontiers in medicine · 2026Article
- Article
- Incorporating Continuous Mammographic Density Into the BOADICEA Breast Cancer Risk Prediction Model.JCO precision oncology · 2025Article
- Molecular Breast Imaging and Digital Breast Tomosynthesis for Dense Breast Screening: The Density MATTERS Trial.Radiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHigh breast density is an independent risk factor for breast cancer and decreases the sensitivity of mammography. This systematic review synthesizes the international clinical guidelines and the evidence base for screening and supplemental screening recommendations in women with dense breasts.
methodsA systematic search of CINHAL, Embase, and Medline databases was performed in August 2023 and grey literature searched in January 2024. Two authors independently assessed study eligibility and quality (Appraisal of Guidelines for Research and Evaluation II instrument).
resultsOf 3809 articles, 23 guidelines published from 2014 to 2024 were included. The content and quality varied between the guidelines; the average AGREE II total score was 58% (range = 23%-87%). Most guidelines recommended annual or biennial screening mammography for women more than 40 years old with dense breasts (n = 16). Other guidelines recommended breast tomosynthesis (DBT, n = 6) or magnetic resonance imaging (MRI, n = 1) as the preferred screening modality. One third of the guidelines (n = 8) did not recommend supplemental screening for women with dense breasts. Of those that recommended supplemental screening (n = 14), ultrasound was the preferred modality (n = 7), with MRI (n = 3), DBT (n = 3), and contrast-enhanced mammography (n = 2) also recommended.
conclusionsConsensus on supplemental screening in women with dense breasts is lacking. The quality of the guidelines is variable, and recommendations are based largely on low-quality evidence. As evidence of the benefits versus harms of supplemental screening in women with dense breasts is evolving, it is imperative to improve the methodological quality of breast cancer screening and supplemental screening guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.